Hyperbaric oxygen therapy in breast cancer patients

To Comparative Efficacy of Hyperbaric Oxygen Therapy with Neoaduvant Chemotherapy and Surgery with Neoaduvant Chemotherapy and Surgery Per Se in Stage II B Ca Breast Patent : A Prospective Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018258

Enrollment

Registered

2019-03-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Breast cancer patients in Stage 2B Health Condition 2: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Dr. Rijuta Aphale: resident in general surgery Intervention2: HYPERBARIC OXYGEN THERPY TO BE GIVEN TO PATIENTS SUFFERING FROM BREAST CANCER ALONG WITH THEIR ROUTINE CHEMOTHERAPY REGIME:

Eligibility

Inclusion criteria

Inclusion criteria: males and females diagnosed with stage 2B breast cancer of any type will be included in the trial

Exclusion criteria

Exclusion criteria: pregnant females females not giving consent hypertensive females

Design outcomes

Primary

Measure	Time frame
reduction in grade of tumour after therapy reduction in size in 3 cycles at interval of 21 days. margin negativity achievableTimepoint: Total 9 weeks, every 3 weekly assessment of reduction of size of tumour.	—

Secondary

Measure	Time frame
reduction in recurrenceTimepoint: 5 years	—

Countries

India

Contacts

Public ContactDr Rijuta Aphale

Government medical college, bhavnagar

shah.samir@rediffmail.com9427215253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026